7840.T
The company operates in the healthcare services and equipment industry, providing medical equipment, supplies, and distribution services.
Business. 7840.T is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
7840.T is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data.
The company maintains a balanced capital structure with a debt-to-equity ratio of 0.42, indicating a moderate reliance on debt financing. Its liquidity position is characterized by a current ratio of 2.48, suggesting the company can meet its short-term obligations comfortably. However, the company has negative net cash after subtracting total debt, which may pose a liquidity risk.
Profitability metrics show a return on equity (ROE) of 7.26% and a return on assets (ROA) of 4.16%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming in terms of capital efficiency and asset utilization compared to its peers. The gross profit margin is 54.56%, which is in line with the industry median, but the operating margin of 7.69% is below the median, suggesting inefficiencies in operating costs.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The company's revenue is entirely derived from its core operations in the healthcare services and equipment industry.
Looking ahead, the company is projected to experience a modest growth in revenue, with a year-over-year increase of approximately 2.5% in the current fiscal year. This growth is expected to continue into the next fiscal year, albeit at a slightly slower pace. The company's capital expenditure is negative, indicating a reduction in investment in physical assets, which may affect long-term growth potential.
The company faces a medium liquidity risk due to its negative net cash position and a moderate debt load. The risk assessment also indicates a low dilution risk, as the number of shares outstanding has remained stable. However, the company's operating cash flow of 7.45 billion JPY is insufficient to cover its long-term debt, which could necessitate future financing activities.
Recent filings and transcripts indicate that the company is focusing on cost optimization and improving operational efficiency. The company has also been exploring new market opportunities to diversify its revenue streams. These strategic initiatives are aimed at enhancing profitability and reducing dependency on a single business segment.
- The company has a moderate debt load and a balanced capital structure, but its liquidity position is constrained by negative net cash.
- Profitability metrics are below industry medians, indicating inefficiencies in capital and asset utilization.
- The company's revenue is concentrated in a single business segment with no geographic diversification, increasing exposure to regional risks.
- The company is projected to experience modest revenue growth, but its capital expenditure is negative, which may affect long-term growth.
- The company faces a medium liquidity risk and is exploring cost optimization and market diversification to enhance profitability.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 7840.T Market data — financials · 2026-05-27
- France Bed Holdings Co Ltd Market data — analyst estimates · 2026-05-27